Ever since the human genetic code was first cracked in 2003, a revolution in the biotechnology sector was spurred in advancing gene-based medical and prescription drug testing and treatment to help people reduce the risk of disease to which they are genetically susceptible and increase the likelihood of drug treatment effectiveness influenced by an individual’s genetic make-up.
Advances in medical science and genomics have contributed to the fast-paced evolution of precision medicine, which is an “emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.”1 Genetic testing and gene-based treatment are exciting DNA-based technologies that can help people live healthier lives. Sixteen years later, these technologies and treatment advancements are rapidly outpacing insurance companies’ and plan sponsors’ adoption of covering this new paradigm of precision medicine. With gene-based testing and therapy increasingly playing a key role in medical treatment, payers of care, including plan sponsors and insurance companies, along with patient management vendors and employees themselves, need to understand how to navigate in this new world.
Please join the Capital Chapter ISCEBS for a panel discussion on this engaging and timely topic and how to incorporate precision medicine into your benefit plans in a strategic, gainful manner with Joe Spinelli, the Chief Commercial Officer at Medtek21 in West Chester, PA and Dave Ratcliffe, Health & Productivity Practice Leader for the Washington, DC office of Buck and Dr. Shanna Ndong, MD, Medical Director Cigna.
Chance to Win: End-of-meeting raffles to be announced for all attendees.
Cancellation Policy: Full refund if requested within 48 hours’ notice of the event.
THANK YOU TO OUR ANNUAL SPONSOR!
Chief Commercial Officer
Joe Spinelli is the Chief Commercial Officer of MedTek21, based in the greater Philadelphia area. The MedTek21 platform proactively identifies risks and remediates medication issues for entire populations through the targeted and cost-effective utilization of pharmacogenomics. Joe is a graduate of Babson College, and previously spent over a decade as an investor and advisor in the venture capital and private equity industries.
Productivity Practice Leader
Dave Ratcliffe is a Principal in the Washington, DC office of Buck, a global integrated HR and benefits consulting, administration, and technology services firm. Dave has advised several clients on establishing precision medicine strategy, including genetic and pharmacogenetic testing, and incorporating it into their benefit plans. He also has consulted to plan sponsors on how to engage employees and other health plan members to best use these new services. A graduate of University of Virginia, Dave has over 25 years of benefits consulting and is a nationally recognized speaker on leading edge benefits.
Dr. Shanna Ndong, MD
Shanna Ndong is a Cigna medical director and is board certified in medical genetics, internal medicine, and pediatrics. After finishing a combined Internal Medicine-Pediatrics residency at the University of Illinois in Chicago, she completed a fellowship in medical genetics at Mount Sinai Medical Center in New York where she was nominated as "Best Pediatric Fellow" and was a member of the House Staff Review Council. Prior to joining Cigna, she worked as a clinical geneticist at NorthShore University Medical Center with a special interest in cancer genetics, developmental delay, and connective tissue disorders. She was a clinician educator at the Pritzker School of Medicine at the University of Chicago and actively participated in medical resident education and recruitment. She has also worked in both primary and urgent care and was a regular contributor of articles on medical topics to her local newspaper ("Athens Now").